Identify upstream targets.
Use an entropy-guided, reverse-causal AI approach to identify potential bottleneck genes in Alzheimer’s disease.
AI for Social Good
Advancing Alzheimer’s drug discovery.
DeepDrugX combines artificial intelligence and neurogenetics to identify potential drug targets and candidates for Alzheimer’s disease.
Our mission spans health, environment, and energy.
Our flagship initiative · DeepDrugX
From biological insight
to research priorities.
Four NAM awards
Healthy Longevity Catalyst Awards, 2021–2024. The only team in Hong Kong to achieve this distinction.
Academic recognition30/1,600
One of 30 semifinalists from 1,600 applications in the NAM Healthy Longevity competition.
NAM Global Innovator Summit 2026Research with purpose
Interdisciplinary expertise in AI, biomedical science, clinical validation, and commercialization.
The people behind ElohaXOur vision
AI for Social Good across health, environment, and energy. Our flagship initiative, DeepDrugX, brings this mission to Alzheimer’s drug discovery.
Trinity (3Ts)
Truth First, Trust First, Transformers (Patients) First!
We are committed to using AI only for Social Good, with ethical and societal stewardship guiding our research and collaborations.
Our research · DeepDrugX
Connecting AI discovery
with biological understanding.
We investigate upstream genes and biological pathways to help researchers prioritize targets and drug candidates for further study.
Connect the biology.
Examine how genetic signals relate to biological pathways, grounding target selection in mechanistic insight.
Prioritize candidates.
Connect potential targets with drug candidates to guide further investigation and experimental validation.
Science & stewardship
Scientific expertise.
Responsible leadership.
Our scientific and advisory leaders guide the research, its governance, and its path toward social impact.
Prof. David Rubinsztein
Scientific Advisor · Cambridge Neurogenetics
Our collaboration integrates expertise in neurodegeneration and genetic research with AI-powered drug discovery.
Mrs. Ingrid Kwok
Chair of Advisory Board
Strategic guidance and governance help place our Alzheimer’s-focused innovations within a framework of sustainability and social impact.
Our team
An international, interdisciplinary team.
Experts in AI, medicine, and linguistics, with experience leading large interdisciplinary projects from research to commercialization.
- AI development & training
- Research innovation
- Medicine / Clinical
- Linguistics / NLP
- Commercialization
Prof. Victor OK Li
Chairman & CEO, Co-Founder
View details
- Expert in AI model development and natural language processing (NLP)
- Professor, Hong Kong University of Science and Technology (Guangzhou)
- Chairman and Co-Founder, Fano (Series B-backed)
- Chair Professor Emeritus, HKU; former Chair Professor, University of Southern California
- S.B., S.M., E.E., and Sc.D., MIT
- Fellow, IEEE, HKIE, IAE, and HKAES
Prof. Jacqueline CK Lam
Deputy Chairwoman & COO, Co-Founder
View details
- Expert in developing novel research approaches, interdisciplinary R&D, and strategy development
- Visiting Associate Professor in Computer Science and Technology, University of Cambridge
- Visiting Scholar, Center for Advanced Study in the Behavioral Sciences (CASBS), Stanford University
- Research Affiliate, MIT CEEPR
- Experience in research funding and international collaboration across health, environment, and energy
Prof. David Rubinsztein
Scientific Advisor
View details
- Expert in neurogenetics
- Professor, University of Cambridge
- Group Leader, UK Dementia Research Institute
- Deputy Director, Cambridge Institute for Medical Research
- FRS, FMedSci
Prof. James Rowe
Scientific Advisor
View details
- Expert in cognitive neurology
- Professor, University of Cambridge
- Associate Director, Dementias Platform UK
- Scientific Advisory Board Chair, Alzheimer’s Research UK
- FMedSci
Dr. Jocelyn Downey
Chief Medical Officer
View details
- Expert in molecular biology
- 13 years of postdoctoral research experience
- Research experience: Scripps; National Institute for Medical Research, UK; University of Cambridge; Imperial College London
Mrs. Ingrid Kwok
Chair of Advisory Board
View details
- Expertise in advisory board leadership and governance
- Strategic development
- Investor readiness and commercialization guidance
Dr. Yang Han
Chief Scientist, CTO
View details
- Expert in AI model training
- Postdoctoral Researcher, CUHK
- Former Research Assistant Professor in AI, HKU (2023–2026)
- MPhil in Technology Policy, University of Cambridge (2020)
- PhD in AI, HKU (2023)
Prof. Lawrence YL Cheung
Director of Language
View details
- Expert in computational linguistics and NLP
- CUHK–Stanford University CASBS Fellow, 2026–27, Center for Advanced Study in the Behavioral Sciences
- Associate Professor in Linguistics, CUHK
- PhD in Linguistics, UCLA (2009)
Founded on interdisciplinary research. Prof. Victor Li brings engineering, AI, and entrepreneurial strategy; Prof. Jacqueline Lam brings interdisciplinary research leadership, research funding, and international collaboration. As Director and Co-Director of HKU-AI WiSe, they connect academic expertise with ElohaX’s AI for Social Good mission.
Research connections
Collaboration across
disciplines and borders.
Long-term research collaborations with local and international universities.
The people behind
the research.
Moments with the ElohaX team, our co-founders, and advisory leadership.
Photo 1 of 7
Pictures of the ElohaX Team (with Prof. Victor Li, Co-founder, Prof. Jacqueline Lam, Co-founder, and Mrs. Ingrid Kwok, Chair of Advisory Board)
ElohaX in the research community
Recognition
NAM awards and conference milestones supporting our Alzheimer’s research.
Featured appearance2026
U.S. National Academy of Medicine
Catalyzing Healthy Longevity:
NAM Global Innovator Summit
Explore the presentation
Explore the research.
Interactive presentation
The one-minute pitch
An interactive introduction to ElohaX, DeepDrug’s approach, and opportunities to collaborate.
Explore the pitch (opens in a new tab)
Conference poster
Finding upstream targets for Alzheimer’s drug discovery
An entropy-guided, reverse-causal AI approach to identifying upstream bottleneck genes and potential drug candidates.
A closer look
Watch the poster walkthrough.
A narrated tour of the research question, the five-step AI platform, and the evidence behind our work.
Research milestones
Four years of
Catalyst Award recognition.
Four consecutive NAM Healthy Longevity Catalyst Awards, from 2021 to 2024, supported the research foundations behind DeepDrug.
Graph AI
Alzheimer’s drug repurposing and the network backbone.
Causal AI
Upstream genetic biomarkers and the causal layer.
Multimodal AI
A multimodal platform for Alzheimer’s prediction.
Speech-based AI
LLM-driven speech analysis for Alzheimer’s prediction.
Research milestones are summarized in the conference poster (opens in a new tab).
Get in touch
Let’s move the
research forward.
Connect with our founders about research, scientific collaboration, and opportunities to work together.
Prof. Victor OK Li
Chairman & CEO, Co-Founder
vli@eee.hku.hkProf. Jacqueline CK Lam
Deputy Chairwoman & COO, Co-Founder
jcklam@eee.hku.hk